Targeted therapies don't work for a reason; the neglected tumor suppressor phosphatase PP2A strikes back

Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer

(2018) Kimberly McClinch et al.   CANCER RESEARCH

Tumor suppressive protein phosphatases in human cancer: Emerging targets for therapeutic intervention and tumor stratification

(2018) Bob Meeusen et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Phosphatases catching up with the level of knowledge: Finally druggable?

(2018) Jukka Westermarck   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

A fine balancing act: A delicate kinase-phosphatase equilibrium that protects against chromosomal instability and cancer

(2018) Marilia Henriques Cordeiro et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Non-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer

(2018) Otto Kauko et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Therapeutic targeting of PP2A

(2018) Caitlin M. O’Connor et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells

(2018) Otto Kauko et al.   Science Translational Medicine

Targeted activation of the SHP-1/PP2A signaling axis elicits apoptosis of chronic lymphocytic leukemia cells

(2017) Elena Tibaldi et al.   HAEMATOLOGICA

Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth

(2017) Jaya Sangodkar et al.   JOURNAL OF CLINICAL INVESTIGATION

Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration

(2017) Ariadna Tibau et al.   JNCI-Journal of the National Cancer Institute

The most popular genes in the human genome

(2017)   NATURE

Targeted activation of the SHP-1/PP2A signaling axis elicits apoptosis of chronic lymphocytic leukemia cells

(2017) Elena Tibaldi et al.   HAEMATOLOGICA

Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration

(2017) Ariadna Tibau et al.   JNCI-Journal of the National Cancer Institute

Regulation of protein phosphatase 2A (PP2A) tumor suppressor function by PME-1

(2016) A. Kaur et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

The Emerging Role of Tyrosine Kinase Inhibitors in Ovarian Cancer Treatment: A Systematic Review

(2016) Ioannis Ntanasis-Stathopoulos et al.   CANCER INVESTIGATION

PP2A Inhibitor PME-1 Drives Kinase Inhibitor Resistance in Glioma Cells

(2016) Amanpreet Kaur et al.   CANCER RESEARCH

Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer

(2016) Justin M. Drake et al.   CELL

Targeting the Breast Cancer Kinome

(2016) Samantha M. Miller et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer

(2016) Shaokun Shu et al.   NATURE

Proteogenomics connects somatic mutations to signalling in breast cancer

(2016) Philipp Mertins et al.   NATURE

Cip2a promotes cell cycle progression in triple-negative breast cancer cells by regulating the expression and nuclear export of p27Kip1

(2016) H Liu et al.   ONCOGENE

Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia

(2016) Nameeta P. Richard et al.   Oncotarget

Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients

(2015) C M Lucas et al.   LEUKEMIA

Protein Phosphatase 2A Inhibition with LB100 Enhances Radiation-Induced Mitotic Catastrophe and Tumor Growth Delay in Glioblastoma

(2015) I. K. Gordon et al.   MOLECULAR CANCER THERAPEUTICS

Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy

(2015) R Mandal et al.   ONCOGENE

PP2A: The Achilles Heal in MDS with 5q Deletion

(2014) David A. Sallman et al.   Frontiers in Oncology

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies

(2013) J. J. Oaks et al.   BLOOD

PP2A function toward mitotic kinases and substrates during the cell cycle

(2013) Ae Lee Jeong et al.   BMB Reports

Cancerous Inhibitor of Protein Phosphatase 2A, an Emerging Human Oncoprotein and a Potential Cancer Therapy Target

(2013) A. Khanna et al.   CANCER RESEARCH

Chk1 Targeting Reactivates PP2A Tumor Suppressor Activity in Cancer Cells

(2013) A. Khanna et al.   CANCER RESEARCH

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

(2013) Paolo Neviani et al.   JOURNAL OF CLINICAL INVESTIGATION

Protein phosphatase 2A: a target for anticancer therapy

(2013) Danilo Perrotti et al.   LANCET ONCOLOGY

Senescence Sensitivity of Breast Cancer Cells Is Defined by Positive Feedback Loop between CIP2A and E2F1

(2013) Anni Laine et al.   Cancer Discovery

Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma

(2012) Hui-Chuan Yu et al.   BIOCHEMICAL PHARMACOLOGY

Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis

(2012) Sahar A. Saddoughi et al.   EMBO Molecular Medicine

CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes

(2012) M Niemelä et al.   ONCOGENE

SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target

(2011) D. J. Christensen et al.   BLOOD

Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2PP2A/SET

(2011) Lisette Arnaud et al.   FEBS LETTERS

ETS1 Mediates MEK1/2-Dependent Overexpression of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) in Human Cancer Cells

(2011) Anchit Khanna et al.   PLoS One

PME-1 Protects Extracellular Signal-Regulated Kinase Pathway Activity from Protein Phosphatase 2A-Mediated Inactivation in Human Malignant Glioma

(2009) P. Puustinen et al.   CANCER RESEARCH

Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias

(2008) Danilo Perrotti et al.   CANCER AND METASTASIS REVIEWS

Structural Mechanism of Demethylation and Inactivation of Protein Phosphatase 2A

(2008) Yongna Xing et al.   CELL

Multiple pathways regulated by the tumor suppressor PP2A in transformation

(2008) Jukka Westermarck et al.   TRENDS IN MOLECULAR MEDICINE